We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Status of treatment strategies for Hutchinson–Gilford progeria syndrome with a focus on prelamin: A posttranslational modification.
- Authors
Chen, Xue; Yao, Haidong; Andrés, Vicente; Bergo, Martin O.; Kashif, Muhammad
- Abstract
Hutchinson–Gilford progeria syndrome (HGPS) is a rare genetic disorder characterized by premature ageing and early death at a mean age of 14.7 years. At the molecular level, HGPS is caused by a de novo heterozygous mutation in LMNA, the gene encoding A‐type lamins (mainly lamin A and C) and nuclear proteins, which have important cellular functions related to structure of the nuclear envelope. The LMNA mutation leads to the synthesis of a truncated prelamin A protein (called progerin), which cannot undergo normal processing to mature lamin A. In normal cells, prelamin A processing involves four posttranslational processing steps catalysed by four different enzymes. In HGPS cells, progerin accumulates as a farnesylated and methylated intermediate in the nuclear envelope where it is toxic and causes nuclear shape abnormalities and senescence. Numerous efforts have been made to target and reduce the toxicity of progerin, eliminate its synthesis and enhance its degradation, but as of today, only the use of farnesyltransferase inhibitors is approved for clinical use in HGPS patients. Here, we review the main current strategies that are being evaluated for treating HGPS, and we focus on efforts to target the posttranslational processing of progerin.
- Subjects
PROGERIA; POST-translational modification; NUCLEAR membranes; NUCLEAR proteins; NUCLEAR shapes; PREMATURE aging (Medicine)
- Publication
Basic & Clinical Pharmacology & Toxicology, 2022, Vol 131, Issue 4, p217
- ISSN
1742-7835
- Publication type
Article
- DOI
10.1111/bcpt.13770